Brenus Pharma unlocks the full potential of immuno-oncology by generating first-in class immunotherapies to initiate a multi-specific in vivo immune response against tumors. Their proprietary “off-the-shelf” Stimulated-tumor-Ghost-Cells (SGC) platform mimics the nature of patients' tumor cells and make it visible to their immune system to anticipate, target and destroy these cells as soon as they appear. Brenus intends to change a paradigm in oncology, by making patients once again actors in their treatment.